The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study
Background: Irritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the...
Gespeichert in:
| Veröffentlicht in: | Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2020-01, Vol.13, p.241-251 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 251 |
|---|---|
| container_issue | |
| container_start_page | 241 |
| container_title | Clinical, cosmetic and investigational dermatology |
| container_volume | 13 |
| creator | Sobhan, Mohammadreza Hojati, Mahsa Vafaie, Seyed-Yaser Ahmadimoghaddam, Davoud Mohammadi, Younes Mehrpooya, Maryam |
| description | Background: Irritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the clinical benefit of colloidal oatmeal cream in the management of chronic irritant HE.
Methods: From October 2018 to November 2019, 79 patients with diagnosis of chronic irritant HE were allocated into either intervention or control groups by block randomization method. Besides fluocinolone 0.025% ointment for the first 2 weeks of treatment period, patients in the intervention and control groups were asked to use colloidal oatmeal 1% cream or base cream for additional 4 weeks as monotherapy. Changes in the HE severity based on the hand eczema severity index (HESCI) score, pruritus severity based on the visual analogue scale (VAS), and impact of skin disorder on patients quality of life based on the Dermatology Life Quality Index (DLQI) from baseline to weeks 2, 4, and 6 were assessed in the study groups.
Results: Fifty subjects, 26 in intervention and 24 in control, completed the course of the study. The results indicated, though relatively comparable decrease in mean HESI and VAS scores was observed in both groups by the end of week 2, thereafter until end of the study a non-return of symptoms to baseline conditions was observed in the intervention group, while there was a significant return of symptoms to baseline conditions in the control group (p value |
| doi_str_mv | 10.2147/CCID.S246021 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A626676200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623569701</galeid><doaj_id>oai_doaj_org_article_a4967694929442b09fa8407d162e3964</doaj_id><sourcerecordid>A623569701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c674t-70f69a8e4dd137c92a0c8f2e08d06497966a8f279feb8833a680e3b785c270683</originalsourceid><addsrcrecordid>eNqNk89v0zAUxyMEYtPYjTOyhOACLf5VO-aAVLLCKg3tsHG2XMdpPSV2cRJQOfOH87qW_pAQLDnYefl-P3kvfi_LnhM8pITLd0UxvRjeUC4wJY-yU0JkPpCYjB4f7E-y87a9w3AxNZIsf5qdMEolk3x0mv26XTg0qSpvjV2hWKEi1nX0panRtekaB2uRnGkQeYVMi8ZlOYgBgSmZ5Qr5gDrwfzHBzF3jQndPWKQYvEXTlHxnIHZpQokm9qdrzHs0Rhexn9Vu8LH2EL7p-nL1LHtSmbp159v1LPv6aXJbXA6urj9Pi_HVwArJOyimEsrkjpclYdIqarDNK-pwXmLBlVRCGHiWqnKzPGfMiBw7NpP5yFKJRc7OsumGW0Zzp5fJNyatdDRe3wdimmuTOm9rpw1XQgrFFVWc0xlWlck5liUR1DElOLA-bFjLfta40kLxydRH0OM3wS_0PH7XkmAmFQXAyy0gxW-9azt9F_sUoH5NmcKcMDYSe9XcQFY-VBFgtvGt1WNBBeRI4Vz_rQKOgkYA1fAvKrhL13gbg6s8xI-wDzTsv_D6wLCA7ukWbaz7zsfQHpP_I9wT326ENsW2Ta7a_WGC9XoE9HoE9HYEQP7i8FR24j8ND4J8I_jhZrFqrXfBup0MZmREqVJUrMeFFNC_64yK2IcOrG8ebmW_AVq8Gco</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2390413356</pqid></control><display><type>article</type><title>The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study</title><source>DOAJ Directory of Open Access Journals</source><source>Dove Press Free</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Access via Taylor & Francis (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sobhan, Mohammadreza ; Hojati, Mahsa ; Vafaie, Seyed-Yaser ; Ahmadimoghaddam, Davoud ; Mohammadi, Younes ; Mehrpooya, Maryam</creator><creatorcontrib>Sobhan, Mohammadreza ; Hojati, Mahsa ; Vafaie, Seyed-Yaser ; Ahmadimoghaddam, Davoud ; Mohammadi, Younes ; Mehrpooya, Maryam</creatorcontrib><description>Background: Irritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the clinical benefit of colloidal oatmeal cream in the management of chronic irritant HE.
Methods: From October 2018 to November 2019, 79 patients with diagnosis of chronic irritant HE were allocated into either intervention or control groups by block randomization method. Besides fluocinolone 0.025% ointment for the first 2 weeks of treatment period, patients in the intervention and control groups were asked to use colloidal oatmeal 1% cream or base cream for additional 4 weeks as monotherapy. Changes in the HE severity based on the hand eczema severity index (HESCI) score, pruritus severity based on the visual analogue scale (VAS), and impact of skin disorder on patients quality of life based on the Dermatology Life Quality Index (DLQI) from baseline to weeks 2, 4, and 6 were assessed in the study groups.
Results: Fifty subjects, 26 in intervention and 24 in control, completed the course of the study. The results indicated, though relatively comparable decrease in mean HESI and VAS scores was observed in both groups by the end of week 2, thereafter until end of the study a non-return of symptoms to baseline conditions was observed in the intervention group, while there was a significant return of symptoms to baseline conditions in the control group (p value<0.001 in both conditions). Further, a noticeable improvement in the DLQI score was seen in the intervention group compared with the control group (p value<0.001).
Conclusion: Findings demonstrate that colloidal oatmeal, a natural product with proven barrier protection, moisturization, anti-inflammatory, and soothing properties, can have ameliorative effects on eczema severity symptoms in patients with chronic irritant HE.</description><identifier>ISSN: 1178-7015</identifier><identifier>EISSN: 1178-7015</identifier><identifier>DOI: 10.2147/CCID.S246021</identifier><identifier>PMID: 32273745</identifier><language>eng</language><publisher>ALBANY: Dove Medical Press Ltd</publisher><subject>Care and treatment ; colloidal oatmeal ; Contact dermatitis ; Cytokines ; Dermatitis ; Dermatology ; dermatology life quality index ; Double-blind studies ; Eczema ; Edema ; Fluocinolone ; hand eczema ; hand eczema severity index ; Hands ; Inflammation ; irritant contact dermatitis ; Life Sciences & Biomedicine ; Lipids ; Original Research ; Patients ; Pharmaceutical industry ; Psoriasis ; Science & Technology ; Skin ; Skin diseases ; Tumor necrosis factor-TNF</subject><ispartof>Clinical, cosmetic and investigational dermatology, 2020-01, Vol.13, p.241-251</ispartof><rights>2020 Sobhan et al.</rights><rights>COPYRIGHT 2020 Dove Medical Press Limited</rights><rights>2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Sobhan et al. 2020 Sobhan et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000522992600001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c674t-70f69a8e4dd137c92a0c8f2e08d06497966a8f279feb8833a680e3b785c270683</citedby><cites>FETCH-LOGICAL-c674t-70f69a8e4dd137c92a0c8f2e08d06497966a8f279feb8833a680e3b785c270683</cites><orcidid>0000-0001-7521-4909 ; 0000-0003-4119-1600 ; 0000-0002-6585-9903 ; 0000-0003-4744-1412</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103792/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103792/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2115,3863,27929,27930,28253,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32273745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sobhan, Mohammadreza</creatorcontrib><creatorcontrib>Hojati, Mahsa</creatorcontrib><creatorcontrib>Vafaie, Seyed-Yaser</creatorcontrib><creatorcontrib>Ahmadimoghaddam, Davoud</creatorcontrib><creatorcontrib>Mohammadi, Younes</creatorcontrib><creatorcontrib>Mehrpooya, Maryam</creatorcontrib><title>The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study</title><title>Clinical, cosmetic and investigational dermatology</title><addtitle>CLIN COSMET INV DERM</addtitle><addtitle>Clin Cosmet Investig Dermatol</addtitle><description>Background: Irritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the clinical benefit of colloidal oatmeal cream in the management of chronic irritant HE.
Methods: From October 2018 to November 2019, 79 patients with diagnosis of chronic irritant HE were allocated into either intervention or control groups by block randomization method. Besides fluocinolone 0.025% ointment for the first 2 weeks of treatment period, patients in the intervention and control groups were asked to use colloidal oatmeal 1% cream or base cream for additional 4 weeks as monotherapy. Changes in the HE severity based on the hand eczema severity index (HESCI) score, pruritus severity based on the visual analogue scale (VAS), and impact of skin disorder on patients quality of life based on the Dermatology Life Quality Index (DLQI) from baseline to weeks 2, 4, and 6 were assessed in the study groups.
Results: Fifty subjects, 26 in intervention and 24 in control, completed the course of the study. The results indicated, though relatively comparable decrease in mean HESI and VAS scores was observed in both groups by the end of week 2, thereafter until end of the study a non-return of symptoms to baseline conditions was observed in the intervention group, while there was a significant return of symptoms to baseline conditions in the control group (p value<0.001 in both conditions). Further, a noticeable improvement in the DLQI score was seen in the intervention group compared with the control group (p value<0.001).
Conclusion: Findings demonstrate that colloidal oatmeal, a natural product with proven barrier protection, moisturization, anti-inflammatory, and soothing properties, can have ameliorative effects on eczema severity symptoms in patients with chronic irritant HE.</description><subject>Care and treatment</subject><subject>colloidal oatmeal</subject><subject>Contact dermatitis</subject><subject>Cytokines</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>dermatology life quality index</subject><subject>Double-blind studies</subject><subject>Eczema</subject><subject>Edema</subject><subject>Fluocinolone</subject><subject>hand eczema</subject><subject>hand eczema severity index</subject><subject>Hands</subject><subject>Inflammation</subject><subject>irritant contact dermatitis</subject><subject>Life Sciences & Biomedicine</subject><subject>Lipids</subject><subject>Original Research</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Psoriasis</subject><subject>Science & Technology</subject><subject>Skin</subject><subject>Skin diseases</subject><subject>Tumor necrosis factor-TNF</subject><issn>1178-7015</issn><issn>1178-7015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>DOA</sourceid><recordid>eNqNk89v0zAUxyMEYtPYjTOyhOACLf5VO-aAVLLCKg3tsHG2XMdpPSV2cRJQOfOH87qW_pAQLDnYefl-P3kvfi_LnhM8pITLd0UxvRjeUC4wJY-yU0JkPpCYjB4f7E-y87a9w3AxNZIsf5qdMEolk3x0mv26XTg0qSpvjV2hWKEi1nX0panRtekaB2uRnGkQeYVMi8ZlOYgBgSmZ5Qr5gDrwfzHBzF3jQndPWKQYvEXTlHxnIHZpQokm9qdrzHs0Rhexn9Vu8LH2EL7p-nL1LHtSmbp159v1LPv6aXJbXA6urj9Pi_HVwArJOyimEsrkjpclYdIqarDNK-pwXmLBlVRCGHiWqnKzPGfMiBw7NpP5yFKJRc7OsumGW0Zzp5fJNyatdDRe3wdimmuTOm9rpw1XQgrFFVWc0xlWlck5liUR1DElOLA-bFjLfta40kLxydRH0OM3wS_0PH7XkmAmFQXAyy0gxW-9azt9F_sUoH5NmcKcMDYSe9XcQFY-VBFgtvGt1WNBBeRI4Vz_rQKOgkYA1fAvKrhL13gbg6s8xI-wDzTsv_D6wLCA7ukWbaz7zsfQHpP_I9wT326ENsW2Ta7a_WGC9XoE9HoE9HYEQP7i8FR24j8ND4J8I_jhZrFqrXfBup0MZmREqVJUrMeFFNC_64yK2IcOrG8ebmW_AVq8Gco</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Sobhan, Mohammadreza</creator><creator>Hojati, Mahsa</creator><creator>Vafaie, Seyed-Yaser</creator><creator>Ahmadimoghaddam, Davoud</creator><creator>Mohammadi, Younes</creator><creator>Mehrpooya, Maryam</creator><general>Dove Medical Press Ltd</general><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7521-4909</orcidid><orcidid>https://orcid.org/0000-0003-4119-1600</orcidid><orcidid>https://orcid.org/0000-0002-6585-9903</orcidid><orcidid>https://orcid.org/0000-0003-4744-1412</orcidid></search><sort><creationdate>20200101</creationdate><title>The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study</title><author>Sobhan, Mohammadreza ; Hojati, Mahsa ; Vafaie, Seyed-Yaser ; Ahmadimoghaddam, Davoud ; Mohammadi, Younes ; Mehrpooya, Maryam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c674t-70f69a8e4dd137c92a0c8f2e08d06497966a8f279feb8833a680e3b785c270683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Care and treatment</topic><topic>colloidal oatmeal</topic><topic>Contact dermatitis</topic><topic>Cytokines</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>dermatology life quality index</topic><topic>Double-blind studies</topic><topic>Eczema</topic><topic>Edema</topic><topic>Fluocinolone</topic><topic>hand eczema</topic><topic>hand eczema severity index</topic><topic>Hands</topic><topic>Inflammation</topic><topic>irritant contact dermatitis</topic><topic>Life Sciences & Biomedicine</topic><topic>Lipids</topic><topic>Original Research</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Psoriasis</topic><topic>Science & Technology</topic><topic>Skin</topic><topic>Skin diseases</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sobhan, Mohammadreza</creatorcontrib><creatorcontrib>Hojati, Mahsa</creatorcontrib><creatorcontrib>Vafaie, Seyed-Yaser</creatorcontrib><creatorcontrib>Ahmadimoghaddam, Davoud</creatorcontrib><creatorcontrib>Mohammadi, Younes</creatorcontrib><creatorcontrib>Mehrpooya, Maryam</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical, cosmetic and investigational dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sobhan, Mohammadreza</au><au>Hojati, Mahsa</au><au>Vafaie, Seyed-Yaser</au><au>Ahmadimoghaddam, Davoud</au><au>Mohammadi, Younes</au><au>Mehrpooya, Maryam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study</atitle><jtitle>Clinical, cosmetic and investigational dermatology</jtitle><stitle>CLIN COSMET INV DERM</stitle><addtitle>Clin Cosmet Investig Dermatol</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>13</volume><spage>241</spage><epage>251</epage><pages>241-251</pages><issn>1178-7015</issn><eissn>1178-7015</eissn><abstract>Background: Irritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the clinical benefit of colloidal oatmeal cream in the management of chronic irritant HE.
Methods: From October 2018 to November 2019, 79 patients with diagnosis of chronic irritant HE were allocated into either intervention or control groups by block randomization method. Besides fluocinolone 0.025% ointment for the first 2 weeks of treatment period, patients in the intervention and control groups were asked to use colloidal oatmeal 1% cream or base cream for additional 4 weeks as monotherapy. Changes in the HE severity based on the hand eczema severity index (HESCI) score, pruritus severity based on the visual analogue scale (VAS), and impact of skin disorder on patients quality of life based on the Dermatology Life Quality Index (DLQI) from baseline to weeks 2, 4, and 6 were assessed in the study groups.
Results: Fifty subjects, 26 in intervention and 24 in control, completed the course of the study. The results indicated, though relatively comparable decrease in mean HESI and VAS scores was observed in both groups by the end of week 2, thereafter until end of the study a non-return of symptoms to baseline conditions was observed in the intervention group, while there was a significant return of symptoms to baseline conditions in the control group (p value<0.001 in both conditions). Further, a noticeable improvement in the DLQI score was seen in the intervention group compared with the control group (p value<0.001).
Conclusion: Findings demonstrate that colloidal oatmeal, a natural product with proven barrier protection, moisturization, anti-inflammatory, and soothing properties, can have ameliorative effects on eczema severity symptoms in patients with chronic irritant HE.</abstract><cop>ALBANY</cop><pub>Dove Medical Press Ltd</pub><pmid>32273745</pmid><doi>10.2147/CCID.S246021</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7521-4909</orcidid><orcidid>https://orcid.org/0000-0003-4119-1600</orcidid><orcidid>https://orcid.org/0000-0002-6585-9903</orcidid><orcidid>https://orcid.org/0000-0003-4744-1412</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-7015 |
| ispartof | Clinical, cosmetic and investigational dermatology, 2020-01, Vol.13, p.241-251 |
| issn | 1178-7015 1178-7015 |
| language | eng |
| recordid | cdi_gale_infotracacademiconefile_A626676200 |
| source | DOAJ Directory of Open Access Journals; Dove Press Free; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via Taylor & Francis (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Care and treatment colloidal oatmeal Contact dermatitis Cytokines Dermatitis Dermatology dermatology life quality index Double-blind studies Eczema Edema Fluocinolone hand eczema hand eczema severity index Hands Inflammation irritant contact dermatitis Life Sciences & Biomedicine Lipids Original Research Patients Pharmaceutical industry Psoriasis Science & Technology Skin Skin diseases Tumor necrosis factor-TNF |
| title | The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T03%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Efficacy%20of%20Colloidal%20Oatmeal%20Cream%201%25%20as%20Add-on%20Therapy%20in%20the%20Management%20of%20Chronic%20Irritant%20Hand%20Eczema:%20A%20Double-Blind%20Study&rft.jtitle=Clinical,%20cosmetic%20and%20investigational%20dermatology&rft.au=Sobhan,%20Mohammadreza&rft.date=2020-01-01&rft.volume=13&rft.spage=241&rft.epage=251&rft.pages=241-251&rft.issn=1178-7015&rft.eissn=1178-7015&rft_id=info:doi/10.2147/CCID.S246021&rft_dat=%3Cgale_pubme%3EA623569701%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2390413356&rft_id=info:pmid/32273745&rft_galeid=A623569701&rft_doaj_id=oai_doaj_org_article_a4967694929442b09fa8407d162e3964&rfr_iscdi=true |